Abstract
Clinically significant insulin resistance is present in most patients with type 2 diabetes mellitus. The only available and effective pharmacotherapy of whole-body insulin resistance consists of pioglitazone treatment.
Imeglimin is a new molecule, primarily acting against insulin resistance. It is supposed that imeglimin intervenes at the level of mitochondrial metabolism with subsequent increase in tissue sensitivity to insulin, glucose uptake by peripheral tissues, and insulin secretion.
Promising results were obtained in phase I and II clinical trials (decrease in glycated hemoglobin concentration by 0.47-0.92% [DCCT], decrease in fasting glycemia, and insulin secretion improvement). Phase III trials were thus scheduled.
At the same time, very low risk of adverse effects was documented.